Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

In vivo evidence of increased nNOS activity in acute MPTP neurotoxicity: a functional pharmacological MRI study.

Siow TY, Chen CC, Wan N, Chow KP, Chang C.

Biomed Res Int. 2013;2013:964034. doi: 10.1155/2013/964034. Epub 2013 Aug 31.

2.

Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity.

Klivenyi P, Andreassen OA, Ferrante RJ, Lancelot E, Reif D, Beal MF.

Neuroreport. 2000 Apr 27;11(6):1265-8.

PMID:
10817604
3.

Unexpected neuronal protection of SU5416 against 1-Methyl-4-phenylpyridinium ion-induced toxicity via inhibiting neuronal nitric oxide synthase.

Cui W, Zhang Z, Li W, Mak S, Hu S, Zhang H, Yuan S, Rong J, Choi TC, Lee SM, Han Y.

PLoS One. 2012;7(9):e46253. doi: 10.1371/journal.pone.0046253. Epub 2012 Sep 25.

5.

Neuroprotective effect of arundic acid, an astrocyte-modulating agent, in mouse brain against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity.

Himeda T, Kadoguchi N, Kamiyama Y, Kato H, Maegawa H, Araki T.

Neuropharmacology. 2006 Mar;50(3):329-44. Epub 2005 Nov 21.

PMID:
16303147
6.

SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease.

Ago Y, Kawasaki T, Nashida T, Ota Y, Cong Y, Kitamoto M, Takahashi T, Takuma K, Matsuda T.

Neuropharmacology. 2011 Dec;61(8):1441-51. doi: 10.1016/j.neuropharm.2011.08.041. Epub 2011 Sep 2.

PMID:
21903118
8.
9.
10.

H MRS identifies lactate rise in the striatum of MPTP-treated C57BL/6 mice.

Koga K, Mori A, Ohashi S, Kurihara N, Kitagawa H, Ishikawa M, Mitsumoto Y, Nakai M.

Eur J Neurosci. 2006 Feb;23(4):1077-81.

PMID:
16519673
11.

Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.

Kurosaki R, Muramatsu Y, Kato H, Watanabe Y, Imai Y, Itoyama Y, Araki T.

Eur Neuropsychopharmacol. 2005 Jan;15(1):57-67.

PMID:
15572274
12.

Sympathetic innervation in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease.

Goldstein DS, Li ST, Holmes C, Bankiewicz K.

J Pharmacol Exp Ther. 2003 Sep;306(3):855-60. Epub 2003 Jun 12.

13.

In vivo NMR studies of regional cerebral energetics in MPTP model of Parkinson's disease: recovery of cerebral metabolism with acute levodopa treatment.

Bagga P, Chugani AN, Varadarajan KS, Patel AB.

J Neurochem. 2013 Nov;127(3):365-77. doi: 10.1111/jnc.12407. Epub 2013 Sep 16.

14.

Nitric oxide: an antioxidant and neuroprotector.

Mohanakumar KP, Thomas B, Sharma SM, Muralikrishnan D, Chowdhury R, Chiueh CC.

Ann N Y Acad Sci. 2002 May;962:389-401. Review.

PMID:
12076990
15.

Endurance exercise training protects against the upregulation of nitric oxide in the striatum of MPTP/probenecid mouse model of Parkinson's disease.

Al-Jarrah M, Obaidat H, Bataineh Z, Walton L, Al-Khateeb A.

NeuroRehabilitation. 2013;32(1):141-7. doi: 10.3233/NRE-130831.

PMID:
23422467
16.
17.
19.
20.

Supplemental Content

Support Center